Retractable Technologies ...

0.69
-0.03 (-4.17%)
At close: Apr 03, 2025, 1:28 PM

Company Description

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally.

It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes.

The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network.

Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.

Retractable Technologies Inc.
Retractable Technologies Inc. logo
Country United States
IPO Date May 4, 2001
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 148
CEO Thomas J. Shaw

Contact Details

Address:
511 Lobo Lane
Little Elm, Texas
United States
Website https://www.retractable.com

Stock Details

Ticker Symbol RVP
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000946563
CUSIP Number 76129W105
ISIN Number US76129W1053
Employer ID 75-2599762
SIC Code 3841

Key Executives

Name Position
Thomas J. Shaw Founder, Chairman, President & Chief Executive Officer
John W. Fort III Vice President, Chief Financial Officer, Principal Accounting Officer,Treasurer & Director
Lawrence G. Salerno Director of Operations
Michele M. Larios Esq. Vice President, General Counsel & Secretary
Russell B. Kuhlman Vice President of Sales Development

Latest SEC Filings

Date Type Title
Apr 01, 2025 4 Filing
Mar 28, 2025 8-K Current Report
Mar 28, 2025 10-K Annual Report
Mar 28, 2025 DEFA14A Filing
Mar 28, 2025 DEF 14A Filing
Mar 28, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 25, 2025 4 Filing
Feb 28, 2025 SCHEDULE 13D/A [Amend] Filing
Feb 20, 2025 4 Filing